Semaglutide, tirzepatide, or sleeve gastrectomy: what 1-year data actually show for type 2 diabetes and obesity

The question we hear most often from people with obesity and type 2 diabetes is some version of this: "My doctor mentioned medication or surgery -- how do I know which one is actually better?" Until recently, the honest answer was that head-to-head data were thin. Trials on GLP-1 medications enrolled people with obesity but not always with diabetes. Bariatric surgery trials rarely had a medication arm. Comparisons across studies were apples and oranges.

A 2025 retrospective cohort study published in Obesity changed that conversation. It put semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and sleeve gastrectomy in the same analysis, looking at adults with both obesity and type 2 diabetes over a full year (https://pubmed.ncbi.nlm.nih.gov/42309121/). The results are not simple, and we are not going to summarize them in a way that makes the decision sound simple. But they give clinicians and patients a shared reference point -- and that matters.

What the study measured and why it matters

The retrospective cohort design means researchers looked back at real-world records rather than conducting a controlled trial. That comes with limitations -- selection bias, unmeasured confounders, differences in who gets which treatment in the first place. People who pursue sleeve gastrectomy and people who start a GLP-1 medication are not identical populations at baseline. The authors attempted to account for this through statistical adjustment, but no retrospective study removes that problem entirely.

With that caveat stated clearly, what the study found at one year lines up with what mechanistic and trial data would predict: sleeve gastrectomy produced the greatest total body weight loss, tirzepatide came in second, and semaglutide produced meaningful but smaller weight loss. On glycemic control -- HbA1c reduction and rates of diabetes remission -- the same rough ranking held, with surgery producing the deepest improvements and semaglutide the most modest.

For context, the SURMOUNT-1 trial had already shown that tirzepatide at 15 mg produced an average body weight reduction of 20.9% at 72 weeks in people without diabetes (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). The STEP-1 trial showed semaglutide at 2.4 mg averaging around 14.9% weight loss at 68 weeks in a similar population (https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). Sleeve gastrectomy consistently produces 25 to 30% excess weight loss in most observational series. The 2025 cohort study brings those three figures into the same frame for a population that had both conditions.

How diabetes remission fits into this

Weight loss and glycemic control move together, but they are not identical. The reason surgery tends to produce faster and deeper diabetes remission than medication is not purely the weight lost -- hormonal and anatomical changes after sleeve gastrectomy alter gut-derived signals, bile acid metabolism, and insulin sensitivity through mechanisms that are at least partly weight-independent (https://pubmed.ncbi.nlm.nih.gov/26832990/).

That is also why tirzepatide's dual mechanism -- targeting both GIP and GLP-1 receptors simultaneously -- produces a glycemic benefit that is meaningfully larger than semaglutide's single-receptor effect. In the SURPASS-2 trial, tirzepatide outperformed semaglutide on HbA1c reduction at every dose tested (https://www.nejm.org/doi/full/10.1056/NEJMoa2107519). The 2025 cohort study reflects that gradient in a real-world population.

What this means practically: for someone with a longer duration of type 2 diabetes, a higher baseline HbA1c, or already-diminished beta-cell function, the gap between surgery and medication may be more clinically significant than it is for someone newly diagnosed with modestly elevated glucose. We individualize that conversation.

The risks that belong in every comparison

Ranking treatments by efficacy without ranking them by risk is incomplete. The three options carry genuinely different risk profiles, and honest clinical care names them.

Sleeve gastrectomy is a permanent anatomical change performed under general anesthesia. Perioperative risk is low at experienced centers but not zero. Micronutrient deficiencies -- particularly iron, vitamin B12, calcium, and vitamin D -- are common after bariatric procedures and require lifelong monitoring and supplementation (https://pubmed.ncbi.nlm.nih.gov/31957213/). GERD can worsen after sleeve in a subset of patients. Reversal is not an option.

Semaglutide and tirzepatide carry a different set of tradeoffs. GI side effects -- nausea, vomiting, constipation -- are common at dose escalation and often improve, though not in every case. A 2025 systematic review flagged respiratory adverse-event signals with GLP-1 receptor agonists that clinicians should keep in mind, particularly for people with existing pulmonary conditions (https://pubmed.ncbi.nlm.nih.gov/42316363/). The findings require more study before they change prescribing broadly, but they underscore that no medication is without a side-effect profile.

Another risk that does not get enough attention in medication discussions is nutritional adequacy. When appetite drops sharply on a GLP-1 medication, total intake drops too -- and if protein and micronutrients do not hold their proportion, lean mass can erode alongside fat. Recent evidence on nutrition care during GLP-1 therapy makes clear that dietary guidance is not optional on these medications; it is part of the protocol (https://pubmed.ncbi.nlm.nih.gov/42323133/). At NoMi Beach Health (NBH), we include nutritional guidance in every weight loss protocol. It is not a bolt-on.

Cardiovascular outcomes: where semaglutide still leads

If your primary concern is long-term cardiovascular risk -- and for people with type 2 diabetes and obesity, it should be part of the conversation -- the evidence base is not symmetric across these three options.

Semaglutide has the most robust cardiovascular outcomes data of any GLP-1 medication currently available. SUSTAIN-6 demonstrated a significant reduction in major adverse cardiovascular events in people with type 2 diabetes (https://www.nejm.org/doi/full/10.1056/NEJMoa1607141). The SELECT trial extended that finding to people without diabetes who had established cardiovascular disease and overweight or obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). No other weight loss medication has that breadth of cardiovascular evidence.

Tirzepatide's dedicated cardiovascular outcomes trial is ongoing, and its results will matter enormously when they arrive. The mechanism is compelling -- improved insulin sensitivity, weight loss, and favorable lipid effects all point toward cardiovascular benefit -- but mechanism is not the same as outcomes data. We are honest about that gap.

For bariatric surgery, large observational studies suggest long-term cardiovascular benefit, and the weight and glycemic improvements are real cardiovascular risk modifiers. But the surgery has not been tested in a randomized trial powered for cardiovascular mortality the way the GLP-1 medications have.

For more depth on how GLP-1 therapies compare on cardiovascular endpoints, our overview at /blog/the-impact-of-glp-1-based-therapies-on-cardiovascular-outcomes-in-type-2-diabete covers the trial landscape in detail.

What this means for the clinical conversation

The 2025 cohort study does not produce a universal winner. It produces better information for a genuinely individualized decision. Here is how we frame that decision in practice.

Surgery tends to make sense when BMI is at or above 35 with significant obesity-related complications, when prior pharmacologic attempts have been inadequate, when the person understands and accepts the permanence and follow-up requirements, and when surgical risk is acceptable. Society guidelines from major diabetes and surgery organizations support metabolic surgery in those parameters (https://pubmed.ncbi.nlm.nih.gov/26832990/).

Tirzepatide tends to make sense when the person wants meaningful weight loss and glycemic control without surgery, when they can commit to indefinite use, when GI tolerability is manageable, and when the cost-coverage equation works. For a direct comparison of semaglutide and tirzepatide across dose, mechanism, and outcomes, our post at /blog/semaglutide-vs-tirzepatide gives a fuller breakdown.

Semaglutide tends to make sense when cardiovascular risk is the central concern, when tirzepatide is not tolerated or accessible, or when the person has already responded well to the medication and wants to optimize. The dose-response data and clinical equivalence between the two agents is something we covered at /blog/dose-response-and-clinical-equivalence-of-semaglutide-and-tirzepatide-for-weight.

None of those three paragraphs is a recommendation for you specifically. They are what clinicians look for when building a treatment plan. Your answer depends on your labs, your cardiovascular history, your diabetes duration and control, your surgical risk, your schedule, your finances, and your preferences.

The thing no headline will tell you

One-year data are useful and honestly better than most of what we had before. They are also one year. The question for someone with type 2 diabetes and obesity is not just "what loses the most weight by month twelve?" It is "what can I sustain, monitor, and manage safely for the next twenty years?"

Surgery is permanent and requires lifelong nutritional follow-up. Medication is reversible but requires indefinite continuation -- stopping semaglutide or tirzepatide is well-documented to result in significant weight regain for most people. Neither of those facts is a disqualifier. They are the tradeoffs an adult deserves to know.

We do not have a preferred modality at NBH. We have a preferred process: look at the full picture, name the evidence, name the tradeoffs, and help you make a decision you can live with -- literally.

What a weight loss evaluation at NBH looks like

When you come in for a weight loss consultation, we are not starting with "which drug do you want?" We are starting with your baseline labs -- fasting glucose, HbA1c, insulin, lipids, thyroid, a metabolic panel, and depending on your history, additional markers. We are looking at your cardiovascular risk, your sleep (because untreated sleep apnea and insulin resistance move together), your current medications, and your history with prior weight loss attempts.

From there, we build a plan that might be medication, might be a referral conversation about surgery, might be both in sequence, and will include nutritional guidance and follow-up labs. We do not hand you a prescription and disappear. We check in at six weeks and three months minimum, and we adjust.

If you have type 2 diabetes and obesity and you are trying to figure out where to start, the answer is a real evaluation -- not a quiz, not a form, and not a 12-minute video call. Book a new-patient visit through our medical weight loss page, or call us at (786) 744-5152. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) will look at your full clinical picture and give you a straight answer.